Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 8;32(5):2658–2675. doi: 10.1096/fj.201700747RR

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s)

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) (http://creativecommons.org/licenses/by-nc/4.0/) which permits noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 8. — Protective efficacy of the recombinant vaccine against a PR8 (H1N1) virus challenge. A, B) The mice immunized (intraperitoneally) with 4 μg RID-HAgD (n = 6) or RID-eGFP control (n = 6), along with the Alum adjuvant, were challenged with 1 times LD₅₀ of the PR8 (H1N1) virus (10³ PFUs), and the body weight changes (A) and survival rates (B) of the infected mice were monitored daily. Immunization with the RID-eGFP control (n = 6) failed to provide protection, and all of these mice (n = 6) succumbed within 7 dpc. C, D) The mice vaccinated intraperitoneally with 20 μg of the mRID-HAgD immunogen (n = 5) or mock infected (PBS control; n = 5) were challenged with 1 times LD₅₀ of the PR8 (H1N1) virus (10³ PFUs), and the body weight changes (C) and survival rates (D) of the infected mice were monitored daily. The mice immunized with 75 μg LysRS-HAgD (n = 5) or 15 μg of the HAgD without RID (n = 5) were also challenged with 1 times LD₅₀ of the PR8 (H1N1) virus (10³ PFUs), and body weight changes of the infected mice were monitored daily (C). Immunization with eLysRS-HAgD or PBS failed to provide protection, and all of these mice (n = 5) succumbed within 7 dpc. Immunization with the HAgD without RID provided partial protection, and only one mouse succumbed within 7 dpc (D). E, F) Replication of the challenge virus in the lungs of the immunized mice. The titers of challenge virus in the lungs were measured by a viral plaque assay. Dashed lines denote a detection limit, 1.0. Error bars indicate the sd of each cohort.